{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["37(12)"],"submitter":["Thuresson PO"],"funding":["F. Hoffmann-La Roche Ltd"],"pubmed_abstract":["<h4>Introduction</h4>Novel treatment options are needed to improve outcomes in transplant-ineligible relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). This systematic literature review evaluated clinical evidence on treatments for patients with R/R DLBCL ineligible for, or relapsed following, stem cell transplantation.<h4>Methods</h4>We assessed the feasibility of conducting an indirect treatment comparison (ITC) or network meta-analysis (NMA) to evaluate the relative efficacy and safety of polatuzumab vedotin in combination with bendamustine + rituximab versus other relevant treatments.<h4>Results</h4>Thirty-seven studies were identified, of which 20 were eligible [seven randomized, controlled trials (RCTs); 13 observational/single-arm trials]. Due to a lack of RCTs, an ITC"],"journal":["Advances in therapy"],"pagination":["4877-4893"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7595978"],"repository":["biostudies-literature"],"pubmed_title":["A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma."],"pmcid":["PMC7595978"],"pubmed_authors":["Thuresson PO","Talbot J","Vander Velde N","Gupta P"],"additional_accession":[]},"is_claimable":false,"name":"A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma.","description":"<h4>Introduction</h4>Novel treatment options are needed to improve outcomes in transplant-ineligible relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). This systematic literature review evaluated clinical evidence on treatments for patients with R/R DLBCL ineligible for, or relapsed following, stem cell transplantation.<h4>Methods</h4>We assessed the feasibility of conducting an indirect treatment comparison (ITC) or network meta-analysis (NMA) to evaluate the relative efficacy and safety of polatuzumab vedotin in combination with bendamustine + rituximab versus other relevant treatments.<h4>Results</h4>Thirty-seven studies were identified, of which 20 were eligible [seven randomized, controlled trials (RCTs); 13 observational/single-arm trials]. Due to a lack of RCTs, an ITC","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2025-04-04T20:02:40.138Z","creation":"2020-11-19T11:33:25Z"},"accession":"S-EPMC7595978","cross_references":{"pubmed":["33001384"],"doi":["10.1007/s12325-020-01507-7"]}}